Home / Clinical trials / Exenatide
Are there clinical trials for Exenatide?
Exenatide has 380 registered clinical trials, including 243 completed interventional studies and trials reaching Phase 4. Its use in humans is supported by established registered clinical evidence.
Trial breakdown
By phase
| Phase 3 | 93 |
| Phase 4 | 87 |
| Phase 2 | 74 |
| Phase 1 | 59 |
| Not applicable | 39 |
| Early Phase 1 | 5 |
By status
| Completed | 275 |
| Unknown status | 51 |
| Terminated | 22 |
| Recruiting | 12 |
| Withdrawn | 12 |
| Active, not recruiting | 6 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
Active trials
- A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapyNot yet recruiting · 3718 participants · Novartis Pharmaceuticals · started 2026-10-30NCT07881783
- Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma LocalizationNot applicable · Recruiting · 20 participants · Peking Union Medical College Hospital · started 2026-10-01NCT07808879
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsRecruiting · 300 participants · Ohio State University · started 2026-06-12NCT07702461
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisPhase 2 · Recruiting · 120 participants · Johns Hopkins University · started 2026-04-28NCT07497399
- A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes MellitusEarly Phase 1 · Recruiting · 9 participants · The First Affiliated Hospital of Henan University of Science and Technology · started 2026-01-20NCT07347080
- A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney DiseasePhase 2 · Active, not recruiting · 15 participants · Beijing University of Chinese Medicine · started 2025-10-20NCT07907965
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)Active, not recruiting · 23280000 participants · Ohio State University · started 2025-09-15NCT07188545
- Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.Not applicable · Recruiting · 40 participants · Azienda Ospedaliero-Universitaria di Parma · started 2024-10-14NCT06888167
Most recent registered trials
- A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapyNot yet recruiting · 3718 participants · Novartis Pharmaceuticals · started 2026-10-30NCT07881783
- Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma LocalizationNot applicable · Recruiting · 20 participants · Peking Union Medical College Hospital · started 2026-10-01NCT07808879
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsRecruiting · 300 participants · Ohio State University · started 2026-06-12NCT07702461
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisPhase 2 · Recruiting · 120 participants · Johns Hopkins University · started 2026-04-28NCT07497399
- A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes MellitusEarly Phase 1 · Recruiting · 9 participants · The First Affiliated Hospital of Henan University of Science and Technology · started 2026-01-20NCT07347080
- A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney DiseasePhase 2 · Active, not recruiting · 15 participants · Beijing University of Chinese Medicine · started 2025-10-20NCT07907965
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)Active, not recruiting · 23280000 participants · Ohio State University · started 2025-09-15NCT07188545
- Assessment of Safety, Tolerability and Drug Levels of Exenatide ImplantPhase 1 · Completed · 24 participants · Vivani Medical, Inc · started 2024-12-20NCT05670379
- Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.Not applicable · Recruiting · 40 participants · Azienda Ospedaliero-Universitaria di Parma · started 2024-10-14NCT06888167
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsRecruiting · 24000 participants · AstraZeneca · started 2024-09-30NCT05663515
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in BangladeshPhase 4 · Unknown status · 938 participants · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · started 2024-09NCT06449235
- Exenatide For Reducing the Reinforcing Effects of CocainePhase 1 · Withdrawn · Christopher D. Verrico · started 2024-08-01NCT06252623
What Exenatide is being studied for
Most studied conditions
Who is running the studies
Counted from ClinicalTrials.gov registrations, checked 2026-11-09.
Peptides with a similar weight of evidence
Ordered by how far the registered research has progressed.
- Octreotide328 registered studies
- Tirzepatide312 registered studies
- Teriparatide182 registered studies
- Dulaglutide143 registered studies
- Desmopressin127 registered studies
Frequently asked questions
Are there clinical trials for Exenatide?
Exenatide has 380 registered clinical trials, including 243 completed interventional studies and trials reaching Phase 4. Its use in humans is supported by established registered clinical evidence.
Does a registered trial mean the peptide works?
No. Registration means a study was formally listed before or during the research. It says nothing about the result. A completed trial can find no benefit, and many registered studies are never published.
What is the difference between a registered trial and published evidence?
Registration records that a study exists. Publication reports what it found. This page counts registrations, which is the more complete picture of research activity, but it is not a measure of proven effectiveness.
Why do phases matter?
Phase 1 tests safety in a small group. Phase 2 looks for early signs of effect. Phase 3 tests effectiveness against a comparator in a large group, and is what regulators normally require. Phase 4 studies happen after approval. A compound with only Phase 1 trials has not been shown to work.
Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine. Studies where Exenatide is registered as an intervention. Last updated 2026-11-09.
Related data
- When generic exenatide arrives →FDA patent and exclusivity expiry dates
- Which peptides are FDA-approved →Approval status for every peptide, from Drugs@FDA
- Which peptides have clinical evidence →Registered clinical trial counts from ClinicalTrials.gov
- Peptide legality by US state →A sourced verdict for all 50 states
